Notice of Interim Results

RNS Number : 1464X

Oxford Biomedica PLC

25 August 2022

 

Notice of Interim Results

Oxford, UK - 25 August 2022:  Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2022 on Thursday 15 September 2022.

A virtual briefing for analysts will be held at 13:00 BST / 08.00 ET on the day of the results with a Q&A session. The webcast and conference call details will be made available on the Company's website at www.oxb.com. A replay of the presentation will be made available shortly afterwards.

-Ends-

Enquiries: 

Oxford Biomedica plc: T: [phone] / E: [e-mail]

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Matthew Cole / Angela Gray

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

 

END

 

 

NORFZLLLLVLBBBB